SLE-key Technology

The iCHIP® Solution

The SLE-key® Rule Out test is based on the ImmunArray iCHIP®, a groundbreaking in-vitro autoantibody profiling platform.  The iCHIP® provides a detailed view of the immune system based on a panel of 200 printed antigens.  iCHIP® data can provide either a snapshot of a single time point or be used to monitor autoantibody profiles over time.  Profiling over time may be used  to monitor and predict disease, and treatment outcomes.

Slide_Configuration

Technology Platform

iCHIP®s are printed antigen microarrays with 100s of antigens. Proprietary analytics are utilized to monitor iCHIP® manufacturing, and for identifying and interpreting antibody signatures. The iCHIP® Technology includes customizable application chips with 100s of antigens, granting flexibility in potential diagnostic capabilities outside of SLE. iCHIP® is a scalable chip manufacturing platform that is amendable to automation, and  allows for sensitive and specific testing and readout procedure.

iCHIP® Technology Platform
A proprietary microarray of antigens

iCHIP® Products
A custom application of technology

  • Stable platform with 100s of antigens
  • Rapid identification of disease-specific immune signatures
  • Allows isotyping

  • Disease- or product-specific antigen arrays
  • Carries variable numbers of antigens (5-100)
  • Highly sensitive (detection of antibodies)
  • Directly applicable in our service laboratory

Precision Medicine

ImmunArray uses commercially-available readers for fluorescence detection and analysis, proprietary software to analyze antibody signal and profile responses, and a proprietary database to interpret responses for a particular disease application. Future products using the iCHIP® technology are aimed at immuno-oncology, traumatic brain injury, transplantation medicine, multiple sclerosis, and other disorders. Testing is performed in company-owned service laboratory facility in Richmond Virginia.

The iCHIP® proprietary technology is potentially a significant improvement over current precision medicine alternatives as it:

  • requires minimal sample volume
  • potentially identifies disease prior to irreversible injury
  • predicts response prior to therapy
  • objectively defines uniform clinical trial phenotypes
  • may accelerate development via defining responsive cohorts
  • provides for early termination of ineffective candidate compounds

Use of an iCHIP® in immune-mediated diseases may mirror the increasingly common trend favoring use of companion diagnostics (providing essential information regarding safe and effective use of a particular therapeutic product). Autoantibody response assays could become a requirement in the development of selected drugs, turning into a ‘gatekeeper’ for reimbursement.

The iCHIP® assesses the immune system, creating the potential for optimized, patient-specific diagnosis and therapy management (“Precision Medicine”).

iCHIP® tests evaluate the immune system as a whole:

  • Analysis via the immune system’s autoantibody response profile
  • Potentially enables dynamic monitoring longitudinally
  • Identification of diseases prior to irreversible damage
  • Prediction of response prior to therapy and monitoring of therapeutic response